Cas:482583-71-1 1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI) manufacturer & supplier

We serve Chemical Name:1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI) CAS:482583-71-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI)

Chemical Name:1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI)
CAS.NO:482583-71-1
Synonyms:1H-Pyrrole-3-carboxylic acid, 5-formyl-1-methyl-;5-Formyl-1-methyl-1H-pyrrole-3-carboxylic acid;1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI)
Molecular Formula:C7H7NO3
Molecular Weight:153.135
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:358.1±27.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.565
PSA:59.30000
Exact Mass:153.042587
LogP:0.22

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1H-Pyrrole-3-carboxylic acid, 5-formyl-1-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1H-Pyrrole-3-carboxylicacid,5-formyl-1-methyl-(9CI) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Formyl-1-methyl-1H-pyrrole-3-carboxylic acid Use and application,1H-Pyrrole-3-carboxylic acid, 5-formyl-1-methyl- technical grade,usp/ep/jp grade.


Related News: In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion. 1-(13,24,33,43,53,63-hexaoxin-2-yl)-2-((hydroxy-24-trioxidaneyl)oxy)-14,23,33-trioxidane-1,3-dione manufacturers Capturing multiple aspects of improvement increases confidence that anifrolumab may be an important option for patients.” 1-(2,4-dichloro-5-propoxyphenyl)-4-methyl-1,4-dihydro-5H-tetrazol-5-one suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. 1-(7-Acetyl-3,6a,7,8,9,12a-hexahydro-2H-6,12-dioxa-1,7-diaza-dibenzo[def,mno]chrysen-1-yl)-ethanone vendor & factory.